Pathophysiology and management of neurocardiogenic syncope

American Journal of Managed Care

Volumn 9, Issue 4, 2003, Pages 327-334

  Nair, Nandini ^a   Padder, Farooq A ^a   Kantharia, Bharat K ^a  

^a DREXEL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ATENOLOL; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DISOPYRAMIDE; ETILEFRINE; FLUDROCORTISONE ACETATE; FLUOXETINE; GLYCERYL TRINITRATE; ISOPRENALINE; METHYLXANTHINE DERIVATIVE; MIDODRINE; MINERALOCORTICOID; PAROXETINE; PINDOLOL; PLACEBO; PROPANTHELINE BROMIDE; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THEOPHYLLINE; TRANQUILIZER; VASODILATOR AGENT;

ANEMIA; ANXIETY; ARTIFICIAL HEART PACEMAKER; BLOOD DONOR; BLOOD VOLUME; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONCENTRATION RESPONSE; CONGESTIVE HEART FAILURE; CONSTIPATION; DIAPHORESIS; DIURESIS; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPNEA; FLUID RETENTION; GASTROINTESTINAL DISEASE; HEAD TILTING; HEADACHE; HEART PACING; HEART PALPITATION; HEART PROARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOVOLEMIA; LOW DRUG DOSE; NAUSEA; NERVOUSNESS; PARESTHESIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STANDING; SYNCOPE; THORAX PAIN; TREATMENT PLANNING; URINARY HESITANCY; URINE RETENTION; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ARRHYTHMIA; CARDIAC PACING, ARTIFICIAL; CARDIOVASCULAR ABNORMALITIES; CHOLINERGIC ANTAGONISTS; EDUCATION, MEDICAL, CONTINUING; HEAD-DOWN TILT; HUMANS; MANAGED CARE PROGRAMS; MINERALOCORTICOIDS; PROGNOSIS; SEROTONIN UPTAKE INHIBITORS; SYNCOPE, VASOVAGAL; UNITED STATES; XANTHINES;

EID: 0038079386     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Savage DD, Corwin L, McGee DL, Kannel WB, Wolf PA. Epidemiologic features of isolated syncope: The Framingham Study. Stroke. 1985;16:626-629.
2. Kapoor WN, Karpf M, Wieland S, et al. A prospective evaluation and follow-up of patients with syncope. N Engl J Med. 1983;309:197-204.
3. Abboud F. Neurocardiogenic syncope. N Engl J Med. 1993;328:1117-1120.
4. Rea R, Thomas MD. Neural control and vasovagal syncope mechanisms. J Cardiovasc Electrophysiol. 1993;4:587-595.
5. Furlan RR, Piazza S, Dell'Orto S, et al. Cardiac autonomic patterns preceding occasional vasovagal reactions in healthy humans. Circulation. 1998;98:1756-1761.
6. Van Lieshout JJ, Wieling W, Karmeker JM, Eckberg DL. The vasovagal response. Clin Sci. 1991;81:575-586.
7. Thoren P. Role of cardiac vagal C-fibers in cardiovascular control. Rev Physiol Biochem Pharmacol. 1979;86:1-94.
8. Mark A. The Bezold-Jarisch reflex revisited: Clinical implications of inhibitory reflexes originating in the heart. J Am Coll Cardiol. 1983; 1: 90-102.
9. Boorin MR. Anxiety: Its manifestation and role in the dental patient. Dent Clin North Am. 1995;39:523-539.
10. Bou-Holaigah I, Rowe PC, Kan J, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA. 1995;274:961-967.
11. Milstein S, Buetikofer J, Lesser J, et al. Cardiac asystole: A manifestation of neurally mediated hypotension-bradycardia. J Am Coll Cardiol. 1989;14:1626-1632.
12. Folino AF, Buja GF, Martini B, Miorelli M, Nava A. Prolonged cardiac arrest and complete AV block during upright tilt test in young patients with syncope of unknown origin: Prognostic and therapeutic implications. Eur Heart J. 1992;13:1416-1421.
13. Grubb BP, Gerard G, Roush K, et al. Differentiation of convulsive syncope and epilepsy with head up tilt testing. Ann Intern Med. 1991;115:871-876.
14. Pennington J, Kantharia B, Zado E, et al. Long-term follow up in patients with a malignant head up tilt table test study (asystole > 5 seconds). Arch Mal Coeur Vaiss. 1998;91:11-13.
15. Kapoor WN. Current evaluation and management of syncope. Circulation. 2002;106:1606-1609.
16. Kapoor WN. Using a tilt table to evaluate syncope. Am J Med Sci. 1999;317:110-116.
17. Sutton R, Bloomfield DM. Indications, methodology and classification of results of tilt-table testing. Am J Cardiol. 1999;84: 10-19.
18. Almquist A, Goldenberg IF, Milstein S, et al. Provocation of bradycardia and hypotension by isoproterenol and upright posture in patients with unexplained syncope. N Engl J Med. 189;320:346-351.
19. Sneddon JF, Slade A, Seo H, Camm AJ, McKenna WJ. Assessment of the diagnostic value of head-up tilt testing in the evaluation of syncope in hypertrophic cardiomyopathy. Am J Cardiol. 1994;73:601-604.
20. Shen WK, Jahangir A, Beinborn D, et al. Utility of a single-stage isoproterenol tilt table test in adults: A randomized comparison with passive head-up tilt. J Am Coll Cardiol. 1999;33:985-990.
21. Zeng C, Zhu Z, Hu W, et al. Value of sublingual isosorbide dinitrate before isoproterenol tilt test for diagnosis of neurally mediated syncope. Am J Cardiol. 1999;83:1059-1063.
22. Mittal S, Stein KM, Markowitz SM, et al. Induction of neurally mediated syncope with adenosine. Circulation. 1999;99:1318-1324.
23. Di Girolamo E, Di Iorio C, Leonzio L, Sabatini P, Barsotti A. Usefulness of a tilt training program for the prevention of refractory neurocardiogenic syncope in adolescents: A controlled study. Circulation. 1999;100:1798-1801.
24. Morillo CA, Leitch JW, Yee R, Klein GJ. A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tilt. J Am Coll Cardiol. 1993;22:1843-1848.
25. Moya A, Permanyer-Miralda G, Sagrista-Sauleda J, et al. Limitations of head-up tilt test for evaluating the efficacy of therapeutic interventions in patients with vasovagal syncope: Results of a controlled study of etilefrine versus placebo. J Am Coll Cardiol. 1995;25:65-69.
26. Younoszai AK, Franklin WH, Chan DP, Cassidy SC, Allen HD. Oral fluid therapy: A promising treatment for vasodepressor syncope. Arch Pediatr Adolesc Med. 1998;152:165-168.
27. Schatz IJ. Management of orthostatic hypotension. In: Schatz IJ, ed. Orthostatic Hypotension. Philadelphia, PA: FA Davis; 1986:98.
28. Cox MM, Perlman BA, Mayor MR, et al. Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope. J Am Coll Cardiol. 1995;26:1293-1298.
29. Biffi M, Boriani G, Sabbatini P, et al. Malignant vasovagal syncope: A randomized trial of metoprolol and clonidine. Heart. 1997;77:268-272.
30. Blanc JJ, Corbel C, Maqnsourati J, Genet L. Evaluation of beta-adrenergic blockade therapy in vasovagal syncope reproduced by head-up tilt test. Arch Mal Coeur Vaiss. 1991;84:1453-1457.
31. Sra JS, Murphy VS, Jazayeri MR, et al. Use of intravenous esmolol to predict efficacy of oral beta blocker therapy in patients with neurocardiogenic syncope. J Am Coll Cardiol. 1992;19:402-408.
32. Cohen MB, Snow JS, Grasso V, et al. Efficacy of pindolol for treatment of vasovagal syncope. Am J Cardiol. 1995;130:786-790.
33. Yu SC, Sung RJ. Clinical efficacy of propantheline bromide in neurocardiogenic syncope: Pharmacodynamic implications. Cardiovasc Drugs Ther. 1997;10:687-692.
34. Kosinski D, Grubb BP, Temesy-Armos P. Pathophysiologic aspects of neurocardiogenic syncope: Current concepts and new perspectives. Pacing Clin Electrophysiol. 1995;18:716-724.
35. Samoil A, Grubb BP. Neurally mediated syncope and serotonin reuptake inhibitors. Clin Auton Res. 1995;5:251-255.
36. Grubb BP. SSRIs for vasodepressor syncope? Postgrad Med. 2000;108:29-32.
37. Grubb BP, Samoil D, Kosinski D, Kip K, Brewster P. The use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents. J Am Coll Cardiol. 1994;24:490-494.
38. Grubb BP, Wolfe DA, Samoil D, et al. Usefulness of fluoxetine hydrochloride in the treatment of resistant upright tilt-induced syncope. Pacing Clin Electrophysiol. 1993;16:458-464.
39. Di Girolamo E, Di Lorio C, Sabatini P, et al. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1999;33:1227-1230.
40. Nelson SD, Stanley M, Love CJ, Coyne KS, Schaal SF. The autonomic and hemodynamic effects of oral theophylline in patients with vasodepressor syncope. Arch Intern Med. 1991;151:2425-2429.
41. Raviele A, Brignole M, Sutton R, et al. Effect of etilefrine in preventing syncopal recurrence in patients with vasovagal syncope: A double-blind, randomized, placebo-controlled trial - The Vasovagal Syncope International Study. Circulation. 1999;99:1452-1457.
42. Ward CR, Gray JC, Gilroy JJ, Kenny RA. Midodrine: A role in the management of neurocardiogenic syncope. Heart. 1998;79:45-49.
43. Sheldon R, Koshman ML, Wilson W, Kieser T, Rose S. Effect of dual-chamber pacing with automatic rate-drop sensing on recurrent neurally medicated syncope. Am J Cardiol. 1998;81:158-162.
44. Ammirati F, Colivicchi F, Toscano S, et al. DDD pacing with rate drop response function versus DDI with rate hysteresis pacing for cardioinhibitory vasovagal syncope. Pacing Clin Electrophysiol. 1998;21:2178-2181.
45. Connolly SJ, Sheldon R, Roberts RS, Gent M. The North American Vasovagal Pacemaker Study (VPS): A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol. 1999;33:16-20.
46. Benditt DG, Sutton R, Gammage MD, et al. Clinical experience with Thera DR rate-drop response pacing algorithm in carotid sinus syndrome and vasovagal syncope. The International Rate-Drop Investigators Group. Pacing Clin Electrophysiol. 1997;20:832-839.
47. Petersen ME, Chamberlain-Webber R, Fitzpatrick AP, et al. Permanent pacing for cardioinhibitory malignant vasovagal syndrome. Br Heart J. 1994;71:274-281.
48. Sutton R, Brignole M, Menozzi C, et al. Dual-chamber pacing in the treatment of neurally mediated tilt-positive cardioinhibitory syncope: Pacemaker versus no therapy: A multicenter randomized study. The Vasovagal Syncope International Study (VASIS) Investigators. Circulation. 2000;102:294-299.
49. Ammirati F, Colivicchi F, Santini M. Permanent cardiac pacing versus medical treatment for the prevention of recurrent vasovagal syncope: A multicenter, randomized, controlled trial. Circulation. 2001;104:52-57.
50. Gregoratos G, Abrams J, Epstein AE, et al. Cardiac pacemakers and antiarrhythmia devices. J Am Coll Cardiol. 2002;40:1703-1719.